

**CONTACT - Media:**

Amsterdam	+31.20.550.4488	Brussels	+32.2.509.1392
Lisbon	+351.217.900.029	London	+44.20.7379.2789
New York	+1.212.656.2411	Paris	+33.1.49.27.11.33

**CONTACT - Investor Relations:**

New York	+1.212.656.5700
----------	-----------------

**nyx.com**

Please follow us at:  
[Exchanges Blog](#)  
[Facebook](#)  
[LinkedIn](#)  
[Twitter](#)

**NYSE Euronext Announces Trading Volumes for February 2013**

*Global Derivatives ADV Up 25% Y-o-Y Driven by Strong Fixed Income Trading, Up 71%  
European Cash Equity ADV Up 13% M-o-M; U.S. Cash Equity ADV Up 1% M-o-M  
U.S. Equity Options ADV Up 6% Y-o-Y*

**March 7, 2013** – NYSE Euronext (NYSE) today announced trading volumes for its global derivatives and cash equities exchanges for February 2013<sup>1</sup>. Global derivatives average daily volume (“ADV”) of 8.8 million contracts in February 2013 increased 24.7% compared to February 2012, but decreased 7.6% month-over-month. This increase was primarily driven by stronger European derivatives volume, specifically fixed income derivatives ADV which increased 71% year-over-year. U.S. equity options ADV increased 5.7% compared to February 2012, but decreased 9.8% from January 2013 levels. Trading volumes in European cash equities were down 9.8% year-over-year, but rebounded up 12.8% month-over-month.

**Highlights**

- NYSE Euronext global derivatives ADV in February 2013 of 8.8 million contracts increased 24.7% compared to February 2012, but decreased 7.6% from January 2013 levels.
- NYSE Euronext European derivatives products ADV in February 2013 of 4.4 million contracts increased 54.4% compared to February 2012, but decreased 10.0% from January 2013 levels. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV increased 45.7% compared to February 2012, but decreased by 5.2% from January 2013.
- NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex) ADV of 4.3 million contracts in February 2013 increased 5.7% compared to February 2012 levels but decreased by 5.2% from January 2013 levels. NYSE Euronext's U.S. options exchanges accounted for 28.2% of total U.S. consolidated equity options trading in February 2013.
- NYSE Euronext European cash products ADV of 1.5 million transactions in February 2013 decreased 9.8% compared to February 2012, but increased 12.8% compared to January 2013.

<sup>1</sup> All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

- NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE MKT) handled ADV of 1.6 billion shares in February 2013 decreased 11.9% compared to February 2012 but increased 0.6% compared to January 2013. NYSE Euronext's Tape A matched market share in February 2013 was 29.4%, down from 30.0% in February 2012 and down from 29.7% in January 2013.

Please [click here](#) for the Monthly Transaction Activity Data Table.

###

### **About NYSE Euronext**

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: <http://www.nyx.com>.

### **CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS**

This communication contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "may," "hope," "will," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential," "continue," "could," "future" or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other "forward-looking" information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.

Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE and NYSE Euronext, including future financial results, ICE's and NYSE Euronext's plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE's and NYSE Euronext's filings with the U.S. Securities and Exchange Commission (the "SEC"). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the inability to complete the merger due to the failure of NYSE Euronext stockholders to adopt

the merger agreement or the failure of ICE stockholders to approve the issuance of ICE common stock in connection with the merger; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext's operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE's, NYSE Euronext's or the combined company's respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management's attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled "Risk Factors" in the joint proxy statement/prospectus filed by ICE with the SEC, and as described in ICE's and NYSE Euronext's respective filings with the SEC that are available on the SEC's web site located at [www.sec.gov](http://www.sec.gov), including the sections entitled "Risk Factors" in ICE's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and "Risk Factors" in NYSE Euronext's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, neither ICE nor NYSE Euronext undertakes any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.

#### IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE has filed with the SEC a registration statement on Form S-4, which includes a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext. The final joint proxy statement/prospectus will be delivered to the stockholders of ICE and NYSE Euronext. **INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION.** Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC's website at <http://www.sec.gov>. Investors may also obtain these documents, without charge, from

ICE's website at <http://www.theice.com> and from NYSE Euronext's website at <http://www.nyx.com>

#### PARTICIPANTS IN THE MERGER SOLICITATION

ICE, NYSE Euronext and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the Merger Agreement.

You can find information about ICE and ICE's directors and executive officers in ICE's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 6, 2013, and ICE's proxy statement for its 2012 annual meeting of stockholders, as filed with the SEC on March 30, 2012.

You can find information about NYSE Euronext and NYSE Euronext's directors and executive officers in NYSE Euronext's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 26, 2013, and NYSE Euronext's proxy statement for its 2012 annual meeting of stockholders, filed with the SEC on March 26, 2012.

Additional information about the interests of potential participants will be included in the joint proxy statement/prospectuses, when it becomes available, and the other relevant documents filed by ICE and NYSE Euronext with the SEC.

**NYSE Euronext  
Monthly Volume Summary**

	Average Daily Volume			Total Volume			Average Daily Volume		Total Volume	
	févr-13	févr-12	% Chg	févr-13	févr-12	% Chg	YTD 2013	YTD 2012	YTD 2013	YTD 2012
(Unaudited; contracts in thousands)										
Number of Trading Days - European Cash	20	21		20	21		42		42	
Number of Trading Days - European Derivatives	20	21		20	21		42		42	
Number of Trading Days - U.S. Markets	19	20		19	20		40		40	
<b>European Derivatives Products</b>	<b>4 383</b>	<b>2 839</b>	<b>54,4%</b>	<b>87 653</b>	<b>59 624</b>	<b>47,0%</b>	<b>4 636</b>	<b>52,8%</b>	<b>194 730</b>	<b>49,2%</b>
<i>of which Bclear</i>	667	342	95,0%	14 861	7 181	107,0%	983	12,7%	37 465	95,2%
<b>Total Fixed Income Products</b>	<b>2 736</b>	<b>1 596</b>	<b>71,4%</b>	<b>54 716</b>	<b>33 526</b>	<b>63,2%</b>	<b>2 889</b>	<b>67,7%</b>	<b>121 318</b>	<b>63,8%</b>
Short Term Interest Rate Products	2 487	1 398	77,9%	49 742	29 364	69,4%	2 681	71,4%	112 615	67,4%
Medium and Long Term Interest Rate Products <sup>1</sup>	249	198	25,5%	4 974	4 162	19,5%	207	31,3%	8 703	28,2%
<b>Total Equity Products<sup>2</sup></b>	<b>1 549</b>	<b>1 155</b>	<b>34,1%</b>	<b>30 980</b>	<b>24 262</b>	<b>27,7%</b>	<b>1 655</b>	<b>34,3%</b>	<b>69 498</b>	<b>31,2%</b>
Individual Equity Products	1 026	745	37,7%	20 526	15 652	31,1%	1 152	39,2%	48 372	35,9%
Futures	577	214	169,2%	11 531	4 497	156,4%	689	122,3%	28 953	117,1%
Options	450	531	-15,3%	8 995	11 155	-19,4%	462	-10,7%	19 419	-12,7%
Equity Index Products	523	410	27,5%	10 453	8 610	21,4%	503	24,4%	21 126	21,5%
<i>of which Bclear</i>	657	342	92,0%	14 788	7 181	105,9%	981	12,4%	37 367	94,7%
Individual Equity Products	555	293	89,3%	12 745	6 153	107,1%	865	12,9%	32 492	92,8%
Futures	555	190	192,2%	11 090	3 986	178,2%	673	15,5%	28 273	120,5%
Options	-	103	-	1 654	2 167	-23,7%	192	4,7%	4 220	4,7%
Equity Index Products	102	49	108,7%	2 043	1 028	98,8%	116	9,1%	4 875	108,3%
<b>Commodity Products</b>	<b>98</b>	<b>87</b>	<b>11,9%</b>	<b>1 958</b>	<b>1 836</b>	<b>6,6%</b>	<b>93</b>	<b>14,9%</b>	<b>3 914</b>	<b>12,2%</b>
<b>U.S. Derivatives Products</b>										
<b>Equity Options<sup>3</sup></b>										
NYSE Euronext Options Contracts	4 346	4 110	5,7%	82 574	82 197	0,5%	4 471	8,0%	178 837	8,0%
Total Consolidated Options Contracts	15 399	16 165	-4,7%	292 573	323 293	-9,5%	15 496	-2,6%	619 838	-2,6%
NYSE Group Share of Total	28,2%	25,4%		28,2%	25,4%		28,9%	2,9%	28,9%	2,9%
<b>NYSE Liffe U.S.</b>										
Futures and Futures Options Volume <sup>4</sup>	48,0	88,6	-45,8%	960	1 861	-48,4%	49,5	-46,0%	2 080,0	-46,0%
<b>European Cash Products (trades in thousands)</b>	<b>1 458</b>	<b>1 617</b>	<b>-9,8%</b>	<b>29 163</b>	<b>33 961</b>	<b>-14,1%</b>	<b>1 371</b>	<b>-12,2%</b>	<b>57 599</b>	<b>-14,3%</b>
Equities	1 403	1 564	-10,3%	28 063	32 854	-14,6%	1 319	-12,6%	55 391	-14,6%
Exchange-Traded Funds	15	13	9,0%	294	283	3,8%	14	-5,2%	578	-7,4%
Structured Products	35	34	1,0%	696	723	-3,8%	33	-4,9%	1 378	-7,1%
Bonds	5	5	14,8%	110	100	9,3%	6	28,3%	252	25,3%
<b>U.S. Cash Products (shares in millions)<sup>5</sup></b>	<b>1 563</b>	<b>1 774</b>	<b>-11,9%</b>	<b>29 689</b>	<b>35 488</b>	<b>-16,3%</b>	<b>1 558</b>	<b>-13,2%</b>	<b>62 314</b>	<b>-13,2%</b>
<b>NYSE Listed (Tape A) Issues<sup>4</sup></b>										
Handled Volume <sup>5</sup>	1 123	1 259	-10,8%	21 335	25 181	-15,3%	1 122	-12,0%	44 889	-12,0%
Matched Volume <sup>6</sup>	1 078	1 185	-9,1%	20 477	23 702	-13,6%	1 077	-10,4%	43 071	-10,4%
Total NYSE Listed Consolidated Volume	3 670	3 950	-7,1%	69 725	79 010	-11,8%	3 645	-8,5%	145 781	-8,5%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	30,6%	31,9%	-1,3%	30,6%	31,9%	-1,3%	30,8%	-1,2%	30,8%	-1,2%
Matched Volume <sup>6</sup>	29,4%	30,0%	-0,6%	29,4%	30,0%	-0,6%	29,5%	-0,6%	29,5%	-0,6%
<b>NYSE Arca, MKT and Regional (Tape B) Listed Issues</b>										
Handled Volume <sup>5</sup>	230	258	-10,7%	4 379	5 162	-15,2%	224	-15,6%	8 944	-15,6%
Matched Volume <sup>6</sup>	213	231	-7,4%	4 055	4 610	-12,0%	206	-12,8%	8 249	-12,8%
Total NYSE Arca & MKT Listed Consolidated Volume	1 035	1 127	-8,1%	19 670	22 532	-12,7%	991	-11,5%	39 647	-11,5%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	22,3%	22,9%	-0,6%	22,3%	22,9%	-0,6%	22,6%	-1,0%	22,6%	-1,0%
Matched Volume <sup>6</sup>	20,6%	20,5%	0,1%	20,6%	20,5%	0,1%	20,8%	-0,3%	20,8%	-0,3%
<b>Nasdaq Listed (Tape C) Issues</b>										
Handled Volume <sup>5</sup>	209	257	-18,7%	3 976	5 145	-22,7%	212	-16,5%	8 482	-16,5%
Matched Volume <sup>6</sup>	187	217	-13,7%	3 554	4 335	-18,0%	189	-12,3%	7 554	-12,3%
Total Nasdaq Listed Consolidated Volume	1 892	1 901	-0,5%	35 955	38 024	-5,4%	1 883	1,3%	75 312	1,3%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	11,1%	13,5%	-2,4%	11,1%	13,5%	-2,4%	11,3%	-2,4%	11,3%	-2,4%
Matched Volume <sup>6</sup>	9,9%	11,4%	-1,5%	9,9%	11,4%	-1,5%	10,0%	-1,6%	10,0%	-1,6%
<b>Exchange-Traded Products<sup>5,7</sup></b>										
Handled Volume <sup>5</sup>	220	240	-8,0%	4 186	4 792	-12,6%	214	-13,8%	8 541	-13,8%
Matched Volume <sup>6</sup>	204	214	-4,3%	3 882	4 272	-9,1%	197	-10,7%	7 882	-10,7%
Total ETF Consolidated Volume	1 007	1 085	-7,2%	19 133	21 693	-11,8%	961	-10,9%	38 447	-10,9%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	21,9%	22,1%	-0,2%	21,9%	22,1%	-0,2%	22,2%	-0,7%	22,2%	-0,7%
Matched Volume <sup>6</sup>	20,3%	19,7%	0,6%	20,3%	19,7%	0,6%	20,5%	0,0%	20,5%	0,0%

<sup>1</sup> Data includes currency products.

<sup>2</sup> Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives.

<sup>3</sup> Includes trading in U.S. equity options contracts, not equity-index options.

<sup>4</sup> Includes all volume executed in NYSE Group crossing sessions.

<sup>5</sup> Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots.

<sup>6</sup> Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges.

<sup>7</sup> Data included in previously identified categories.

<sup>\*</sup> ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days.

Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities.

All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells.